Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., Vogelstein, B.·1992·Nature
DOI 10.1038/358080a0

Cited by (1,001)

Items 101–200 of 1,001

  1. MDM2, an introduction.
    Tomoo Iwakuma, Guillermina Lozano · 2003 · PubMed
  2. Alterations of the Notch pathway in lung cancer
    Britta Westhoff, Ivan Nicola Colaluca, Giovanni D’Ario, Maddalena Donzelli, Daniela Tosoni, Sara Volorio, Giuseppe Pelosi, Lorenzo Spaggiari, Giovanni Mazzarol, Giuseppe Viale et al. · 2009 · Proceedings of the National Academy of Sciences
  3. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.
    Gary L. Clayman, Adel K. El‐Naggar, Scott Michael Lippman, Ying C. Henderson, Mitchell J. Frederick, J A Merritt, Louis A. Zumstein, Therese M. Timmons, T.-J. Liu, Lawrence E. Ginsberg et al. · 1998 · Journal of Clinical Oncology
  4. Targeting the MDM2-p53 Interaction for Cancer Therapy
    Sanjeev Kumar Shangary, Shaomeng Wang · 2008 · Clinical Cancer Research
  5. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
    Thomas Stanislawski, Ralf-Holger Voss, Carina Lotz, Elena Sadovnikova, Ralph A. Willemsen, Jurgen H. E. Kuball, Thomas Ruppert, R. L. H. Bolhuis, Cornelius J. M. Melief, Christoph Huber et al. · 2001 · Nature Immunology
  6. Mdm2-mediated ubiquitylation: p53 and beyond
    Marine, J-C, Lozano, G · 2010 · Cell Death & Differentiation
  7. Opposing Effects of Ras on p53
    Ries, Stefan, Biederer, Carola, Woods, Douglas, Shifman, Ohad, Shirasawa, Senji, Sasazuki, Takehiko, McMahon, Martin, Oren, Moshe, McCormick, Frank · 2000 · Cell
  8. Osteosarcoma Development and Stem Cell Differentiation
    Ni Tang, Wenxin Song, Jinyong Luo, Rex C. Haydon, Tong‐Chuan He · 2008 · Clinical Orthopaedics and Related Research
  9. The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53
    Robertson, Keith D., Jones, Peter A. · 1998 · Molecular and Cellular Biology
  10. p53DINP1, a p53-Inducible Gene, Regulates p53-Dependent Apoptosis
    Shu Okamura, Hirofumi Arakawa, Tomoaki Tanaka, Hiroshi Nakanishi, Ching Ching Ng, Yoichi Taya, Morito Monden, Yusuke Nakamura · 2001 · Molecular Cell
  11. Multifactorial analysis of p53 alteration in human cancer: A review
    Thierry Soussi, Yann Legros, Richard Lubin, Katherine Ory, Beata Schlichtholz · 1994 · International Journal of Cancer
  12. mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein
    Jiandong Chen, Xiangwei Wu, Jiayuh Lin, Arnold J. Levine · 1996 · Molecular and Cellular Biology
  13. The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
    Manfredi, James J. · 2010 · Genes & Development
  14. The molecular basis of genetic dominance.
    Andrew O.M. Wilkie · 1994 · Journal of Medical Genetics
  15. MDM2 gene amplification in metastatic osteosarcoma.
    Marc Ladanyi, Charles H. Cha, R Lewis, S.C. Jhanwar, Andrew G. Huvos, John H. Healey · 1993 · PubMed
  16. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction.
    Horst-Werner Stürzbecher, Beate Donzelmann, Wilhelm Henning, Uwe Knippschild, Sabine Buchhop · 1996 · The EMBO Journal
  17. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
    Nabeel M. Bardeesy, David Falkoff, Mary Jane Petruzzi, Norma J. Nowak, Bernhard Zabel, Mohammed Adam, Maria C. Aguiar, Paul Edward Grundy, T.B. Shows, Jerry Pelletier · 1994 · Nature Genetics
  18. Activation of the p53 tumor suppressor protein
    Karen H. Vousden · 2002 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  19. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.
    Barak, Y, Gottlieb, E, Juven-Gershon, T, Oren, M · 1994 · Genes & Development
  20. MDM2 suppresses p73 function without promoting p73 degradation
    Zeng, Xiaoya, Chen, Lihong, Jost, Christine A., Maya, Ruth, Keller, David, Wang, Xinjiang, Kaelin, William G., Oren, Moshe, Chen, Jiandong, Lu, Hua · 1999 · Molecular and Cellular Biology
  21. The tumore suppressor p53
    Lawrence A. Donehower, Allan Bradley · 1993 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  22. Pancreatic adenocarcinomas frequently show p53 gene mutations.
    Aldo Scarpa, P. Capelli, Kiyoshi Mukai, Giuseppe Zamboni, Tatsuya Oda, Calogero Iacono, S Hirohashi · 1993 · PubMed Central
  23. MDM2 interacts with MDMX through their RING finger domains
    Tanimura, Shyu, Ohtsuka, Satoshi, Mitsui, Kaoru, Shirouzu, Kazuo, Yoshimura, Akihiko, Ohtsubo, Motoaki · 1999 · FEBS Letters
  24. Ligand-induced Ubiquitination of the Epidermal Growth Factor Receptor Involves the Interaction of the c-Cbl RING Finger and UbcH7
    Masahiro Yokouchi, Takeshi Kondo, Adam Houghton, Marcjanna Bartkiewicz, William C. Horne, Hui Zhang, Akihiko Yoshimura, Roland Baron · 1999 · Journal of Biological Chemistry
  25. Regulation of p53 Function
    Douglas B. Woods, Karen H. Vousden · 2001 · Experimental Cell Research
  26. The Ribosomal L5 Protein Is Associated with mdm-2 and mdm-2-p53 Complexes
    Vincent Maréchal, Brian Elenbaas, J Piette, J C Nicolas, Arnold J. Levine · 1994 · Molecular and Cellular Biology
  27. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
    Finlay, C A · 1993 · Molecular and Cellular Biology
  28. Activation and activities of the p53 tumour suppressor protein
    Éva Bálint, Karen H. Vousden · 2001 · British Journal of Cancer
  29. p53 stabilization is decreased upon NFκB activation
    Vinay Tergaonkar, Matthew P. Pando, Omid Vafa, Geoffrey M. Wahl, Inder M. Verma · 2002 · Cancer Cell
  30. MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
    Gareth L. Bond, Wenwei Hu, Arnold J. Levine · 2005 · Current Cancer Drug Targets
  31. Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
    Gopa Iyer, Hikmat A Al‐Ahmadie, Nikolaus D. Schultz, Aphrothiti J. Hanrahan, Irina Ostrovnaya, Arjun Vasant Balar, Philip H. Kim, Oscar Lin, Nils Weinhold, Chris Sander et al. · 2013 · Journal of Clinical Oncology
  32. Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents
    Srinivas K. Kumar, Erin R. Hager, Catherine Pettit, Gurulingappa Hallur, Nancy E. Davidson, Saeed R. Khan · 2003 · Journal of Medicinal Chemistry
  33. Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
    Susan E. Morgan, Michael B. Kastan · 1997 · Advances in cancer research
  34. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors
    Frederick F. Lang, Douglas Craig Miller, Maxim Koslow, Elizabeth W. Newcomb · 1994 · Journal of neurosurgery
  35. Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
    Wang, Shaomeng, Zhao, Yujun, Aguilar, Angelo, Bernard, Denzil, Yang, Chao-Yie · 2017 · Cold Spring Harbor Perspectives in Medicine
  36. The Roles of MDM2 and MDMX in Cancer
    Orit Karni-Schmidt, Maria Lokshin, Carol L. Prives · 2016 · Annual Review of Pathology Mechanisms of Disease
  37. Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity
    David S. Franklin, Virginia Godfrey, Deborah A. O’Brien, Chu‐Xia Deng, Yue Xiong · 2000 · Molecular and Cellular Biology
  38. The human MDM-2 oncogene is overexpressed in leukemias
    CE Bueso-Ramos, Yun Sheng Yang, E deLeon, P McCown, Sanford A. Stass, Maher X. Albitar · 1993 · Blood
  39. Modulation of Protein–Protein Interactions with Small Organic Molecules
    Thorsten Berg · 2003 · Angewandte Chemie International Edition
  40. Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
    Sun, Daqing, Li, Zhihong, Rew, Yosup, Gribble, Michael, Bartberger, Michael D., Beck, Hilary P., Canon, Jude, Chen, Ada, Chen, Xiaoqi, Chow, David et al. · 2014 · Journal of Medicinal Chemistry
  41. The INK4a/ARF tumor suppressor: one gene—two products—two pathways
    Lynda Chin, Jason H. Pomerantz, Ronald Anthony DePinho · 1998 · Trends in Biochemical Sciences
  42. TGF-? isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis
    Leslie I. Gold, Tommi Jussila, Norbert E. Fusenig, Frej Stenb�ck · 2000 · The Journal of Pathology
  43. A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
    Federico Bernal, Mark R. Wade, Marina Godes, Tina N. Davis, David G. Whitehead, Andrew L. Kung, Geoffrey M. Wahl, Loren D. Walensky · 2010 · Cancer Cell
  44. Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein
    Sharp, Darcie A., Kratowicz, Stephen A., Sank, Michael J., George, Donna L. · 1999 · Journal of Biological Chemistry
  45. COMMENTARY: p53 Tumor suppressor gene: from the basic research laboratory to the clinic—an abridged historical perspective
    Curtis C. Harris · 1996 · Carcinogenesis
  46. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies
    Ashkan Pouyan, Masoud Ghorbanlo, Masoud Eslami, Majid Jahanshahi, Ehsan Ziaei, Ali Salami, Khatere Mokhtari, Koorosh Shahpasand, Najma Farahani, Tohid Emami Meybodi et al. · 2025 · Molecular Cancer
  47. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression
    Carroll, Patrick E, Okuda, Masaru, Horn, Henning F, Biddinger, Paul, Stambrook, Peter J, Gleich, Lyon L, Li, Ya-Qin, Tarapore, Pheruza, Fukasawa, Kenji · 1999 · Oncogene
  48. A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
    Juliette A. Randerson‐Moor · 2001 · Human Molecular Genetics
  49. A functional p53-responsive intronic promoter is contained within the human<i>mdm2</i>gene
    Zauberman, Arie, Flusberg, Deborah, Haupt, Ygal, Barak, Yaacov, Oren, Moshe · 1995 · Nucleic Acids Research
  50. To die or not to die: how does p53 decide?
    Elizabeth A. Slee, Daniel J O’Connor, Xin Lü · 2004 · Oncogene
  51. Accumulation of p53 in a Mutant Cell Line Defective in the Ubiquitin Pathway
    Dondapati Chowdary, James J. Dermody, K K Jha, H L Ozer · 1994 · Molecular and Cellular Biology
  52. Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1
    Ying Zhao, Shaoli Lu, Lipeng Wu, Guolin Chai, Haiying Wang, Yingqi Chen, Jia Teng Sun, Yu Yu, Wen Zhou, Quanhui Zheng et al. · 2006 · Molecular and Cellular Biology
  53. Cytoplasmic Sequestration of Wild-Type p53 Protein Impairs the G 1 Checkpoint after DNA Damage
    Ute Martha Moll, Anne G. Ostermeyer, Robert Haladay, Blonka Winkfield, Mark Frazier, Gerard P. Zambetti · 1996 · Molecular and Cellular Biology
  54. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
    Sigalas, Iakovos, Calvert, A. Hilary, Anderson, John J., Neal, David E., Lunec, John · 1996 · Nature Medicine
  55. Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
    Raphael Stoll, Christian Renner, Silke Hansen, Stefan Palme, Christian Klein, Anja Belling, Wojciech Żesławski, Mariusz Kamionka, Till Rehm, Peter Mühlhahn et al. · 2000 · Biochemistry
  56. Absence or low number of telomere repeats at junctions of dicentric chromosomes
    Thomas S. K. Wan, Uwe M. Martens, Steven S.S. Poon, Sai‐Wah Tsao, Sy Ha, Peter M. Lansdorp · 1999 · Genes Chromosomes and Cancer
  57. Repression of p53-mediated transcription by MDM2: a dual mechanism
    Thut, Catherine J., Goodrich, James A., Tjian, Robert · 1997 · Genes &amp; Development
  58. Rhabdomyosarcoma – working out the pathways
    Glenn T Merlino, Lee J. Helman · 1999 · Oncogene
  59. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
    Cheau Yun Chen, Jon Oliner, Qimin Zhan, Albert J. Fornace, Bert Vogelstein, Michael B. Kastan · 1994 · Proceedings of the National Academy of Sciences
  60. MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy
    Rayburn, Elizabeth, Zhang, Ruiwen, He, Jie, Wang, Hui · 2005 · Current Cancer Drug Targets
  61. Aberrant Signaling Pathways in Glioma
    Mitsutoshi Nakada, Daisuke Kita, Takuya Watanabe, Yutaka Hayashi, Lei Teng, Ilya V. Pyko, Jun‐ichiro Hamada · 2011 · Cancers
  62. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors
    Avery A. Sandberg, Julia A. Bridge · 2003 · Cancer Genetics and Cytogenetics
  63. The E2F transcription factors: key regulators of cell proliferation
    Heiko Müller, Kristian Helin · 2000 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  64. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
    Andrew L. Folpe, Robert H. Lyles, Jason T. Sprouse, E U Conrad, Janet F. Eary · 2000 · PubMed
  65. Terphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
    Hang Hubert Yin, Gui‐in Lee, Hyung Soon Park, Gregory A. Payne, Johanna M. Rodriguez, Saı̈d M. Sebti, Andrew D. Hamilton · 2005 · Angewandte Chemie International Edition
  66. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes
    Susana Velasco-Miguel, Leonard Buckbinder, Patrice Jean, Larry Gelbert, Randy L. Talbott, Jana L. Laidlaw, Bernd R. Seizinger, Nikolai Kley · 1999 · Oncogene
  67. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
    Aimee Marie Crago, Samuel Singer · 2011 · Current Opinion in Oncology
  68. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
    Carol Midgley, Joana M. P. Desterro, Mark K. Saville, Stephanie F. Howard, Alison Sparks, Ronald T. Hay, David Philip Lane · 2000 · Oncogene
  69. Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn
    Angelika Böttger, Volker Böttger, Carlos Garcı́a-Echeverrı́a, Patrick Chêne, Heinz Kurt Hochkeppel, Wayne R. Sampson, Kiah How Ang, Stephanie F. Howard, Steven M. Picksley, David Philip Lane · 1997 · Journal of Molecular Biology
  70. Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53–MDM2 Pathway
    Hu, Min, Gu, Lichuan, Li, Muyang, Jeffrey, Philip D, Gu, Wei, Shi, Yigong · 2006 · PLoS Biology
  71. The Retinoblastoma Protein: A Master Regulator of Cell Cycle, Differentiation and Apoptosis
    Susanne Herwig, Michael Strauss · 1997 · European Journal of Biochemistry
  72. Apoptosis induced by inhibition of intercellular contact.
    Richard C. Bates, André G. Buret, Dirk F Van Helden, Michael A. Horton, Gordon F. Burns · 1994 · The Journal of Cell Biology
  73. Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53
    Carlos Garcı́a-Echeverrı́a, Patrick Chêne, Marcel J. J. Blommers, Pascal Furet · 2000 · Journal of Medicinal Chemistry
  74. The Role of MDM2 Amplification and Overexpression in Tumorigenesis
    Oliner, Jonathan D., Saiki, Anne Y., Caenepeel, Sean · 2016 · Cold Spring Harbor Perspectives in Medicine
  75. Molecular pathways in the formation of gliomas
    Andreas von Deimling, David N. Louis, Otmar Dieter Wiestler · 1995 · Glia
  76. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone
    Fanny Dujardin, Matthieu Bui Nguyen Binh, Corinne Bouvier, Anne Gomez‐Brouchet, Fréderique Larousserie, Anne De Muret, Caroline Louis‐Brennetot, Alain Aurias, Jean‐Michel Coindre, Louis Guillou et al. · 2011 · Modern Pathology
  77. High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer
    Jan Richter, Urs Wagner, Juha Kononen, André Fijan, James Bruderer, Ulrico Schmid, Daniel Ackermann, Robert E. Maurer, Göran Alund, H Knönagel et al. · 2000 · American Journal Of Pathology
  78. Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26
    Yaara Ofir-Rosenfeld, Kristy Boggs, Dan Michael, Michael B. Kastan, Moshe Oren · 2008 · Molecular Cell
  79. Environmental factors inducing human cancers.
    NZ Parsa · 2012 · Europe PMC (PubMed Central)
  80. <i>mdm2</i> Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
    Mendrysa, Susan M., McElwee, Matthew K., Michalowski, Jennifer, O'Leary, Kathleen A., Young, Karen M., Perry, Mary Ellen · 2003 · Molecular and Cellular Biology
  81. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation
    Andrew R. Pettitt, Paul D. Sherrington, Grant S. Stewart, John C. Cawley, Alexander Malcolm R. Taylor, Tatjana Stanković · 2001 · Blood
  82. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.
    Lundgren, K, Montes de Oca Luna, R, McNeill, Y B, Emerick, E P, Spencer, B, Barfield, C R, Lozano, G, Rosenberg, M P, Finlay, C A · 1997 · Genes &amp; Development
  83. STAT-1 Interacts with p53 to Enhance DNA Damage-induced Apoptosis
    Paul A. Townsend, Tiziano Maria Scarabelli, Sean M. Davidson, Richard A. Knight, David S. Latchman, Anastasis Stephanou · 2004 · Journal of Biological Chemistry
  84. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
    Nacev, Benjamin A., Sanchez-Vega, Francisco, Smith, Shaleigh A., Antonescu, Cristina R., Rosenbaum, Evan, Shi, Hongyu, Tang, Cerise, Socci, Nicholas D., Rana, Satshil, Gularte-Mérida, Rodrigo et al. · 2022 · Nature Communications
  85. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
    Nino Keshelava, J J Zuo, P Chen, S N Waidyaratne, Marian C. Luna, Charles J. Gomer, Timothy Junius Triche, C. Patrick Reynolds · 2001 · PubMed
  86. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
    Helei Hou, Dantong Sun, Xiaochun Zhang · 2019 · Cancer Cell International
  87. Tumor suppressor genes in normal and malignant hematopoiesis
    Utz O. Krug, Arnold Ganser, Harold Phillip Koeffler · 2002 · Oncogene
  88. p53-Mdm2--the affair that never ends
    Dania Alarcon-Vargas · 2002 · Carcinogenesis
  89. Loss of p53 function through PAX‐mediated transcriptional repression.
    E. T. Stuart, Rebecca Haffner, Moshe Oren, P. Gruss · 1995 · The EMBO Journal
  90. MDMX: from bench to bedside
    Marine, Jean-Christophe W., Dyer, Michael A., Jochemsen, Aart G. · 2007 · Journal of Cell Science
  91. aHIF: a Natural Antisense Transcript Overexpressed in Human Renal Cancer and During Hypoxia
    Catherine Thrash-Bingham, Kenneth D. Tartof · 1999 · JNCI Journal of the National Cancer Institute
  92. Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2.
    Ygal Haupt, Yaacov Barak, Moshe Oren · 1996 · The EMBO Journal
  93. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma.
    Mark A. Feitelson, Lifeng Duan · 1997 · Europe PMC (PubMed Central)
  94. p53‐catalyzed annealing of complementary single‐stranded nucleic acids.
    Peter Oberosler, Peter Hloch, Uwe Ramsperger, Hans D. Stahl · 1993 · The EMBO Journal
  95. Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence
    Kensuke Kumamoto, Elisa A. Spillare, Kaori Fujita, Izumi Horikawa, Taro Yamashita, Ettore Appella, Makoto Nagashima, Seiichi Takenoshita, Jun Yokota, Curtis C. Harris · 2008 · Cancer Research
  96. Nup153 is an M9‐containing mobile nucleoporin with a novel Ran‐binding domain
    Sara Nakielny, Sarah Shaikh, Brian Burke, Gideon Dreyfuss · 1999 · The EMBO Journal
  97. Identification and characterization of a p53 homologue in Drosophila melanogaster
    Shengkan V. Jin, Sebastian Martinek, Woo S. Joo, Jennifer Russo Wortman, Nebojša Mirković, Andrej Šali, Mark D. Yandell, Nikola P. Pavletich, Michael W. Young, Arnold J. Levine · 2000 · Proceedings of the National Academy of Sciences
  98. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis?
    Diana M. Barnes, E.A. DUBLIN, C. Fisher, David A. Levison, Rosemary R. Millis · 1993 · Human Pathology
  99. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.
    David G Brachman, M Beckett, Deborah Graves, Daniel J. Haraf, Everett E. Vokes, Ralph R. Weichselbaum · 1993 · PubMed
  100. Hepatitis B virus in hepatocarcinogenesis
    Mark A. Feitelson · 1999 · Journal of Cellular Physiology